Shionogi & Co

Shionogi & Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Shionogi & Co (4507.T) as of Nov 5, 2026 is 1.53. In the previous year, Financial Leverage (Equity Multiplier) was 1.13 — a change of 35.64% (higher).

Financial Leverage

1.53

YoY

35.64%

Last updated:

Financial Leverage (Equity Multiplier) of Shionogi & Co is 2026 1.53 . Financial Leverage (Equity Multiplier) of Shionogi & Co was 2025 1.13 . It decreases by 35.64% higher compared to the previous year.

The Shionogi & Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.17 JPY
Jan 1, 2020
1.14 JPY
Jan 1, 2021
1.18 JPY
Jan 1, 2022
1.18 JPY
Jan 1, 2023
1.19 JPY
Jan 1, 2024
1.15 JPY
Jan 1, 2025
1.13 JPY
Jan 1, 2026
1.53 JPY
The Shionogi & Co Financial Leverage history
YEARFinancial LeverageYoY
1.53+35.64%
1.13-1.71%
1.15-3.82%
1.19+1.12%
1.18-0.12%
1.18+3.40%
1.14-2.05%
1.17-1.46%
1.18-7.73%
1.28+2.19%
1.25-1.24%
1.27+1.82%
1.25—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shionogi & Co Stock analysis

What does Shionogi & Co do? The company Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. It was founded in 1878 and has since become a significant player in the industry. It currently employs over 6,000 employees worldwide and is listed on the Tokyo Stock Exchange. Shionogi is divided into several business segments that offer different products and services. The largest segment is the pharmaceutical division, which specializes in the development and marketing of drugs. The company has strong expertise in infectious diseases, pain management, and oncology, and operates in many countries worldwide. One flagship product is the antibiotic Cefditoren, used to treat various bacterial infections. In addition to the pharmaceutical division, Shionogi is also active in other areas. For example, the company offers diagnostic and laboratory services, operating multiple labs in Japan and other countries. Another business segment is the production and marketing of nutritional supplements, sold in Japan, China, and the USA. Shionogi's business model is based on extensive research and development, as well as strong brand positioning. The company invests a significant portion of its revenue each year in the research and development of new drugs and better treatment options for existing diseases. Thanks to the high quality of its products and strong brand, the company has a loyal customer base. In recent years, Shionogi has focused on international expansion opportunities and has expanded its activities in various regions. For example, it has partnered with US pharmaceutical company Purdue Pharma to develop and market a novel pain medication. Shionogi's annual revenue is around 1.5 billion euros. The company is particularly strong in Japan and other Asian countries, but is also active in the US and Europe. In the coming years, Shionogi aims to further expand its international business and solidify its position as a significant player in the industry. Key focuses will be on the launch of new products and finding treatments for previously incurable diseases. Overall, Shionogi is an innovative and successful company that utilizes its expertise in the pharmaceutical industry in various ways. With its dedicated employees and strong brand, it will continue to play an important role in the industry. Shionogi & Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shionogi & Co stock

Financial Leverage (Equity Multiplier) of Shionogi & Co is 1.53 in 2026.

Financial Leverage (Equity Multiplier) of Shionogi & Co changed from 1.13 to 1.53, representing a 35.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Shionogi & Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Shionogi & Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Shionogi & Co

All Key Metrics — Shionogi & Co